Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Sanofi's Kevzara Fails as a Potential COVID-19 Treatment
by Zacks Equity Research
Sanofi's (SNY) phase III study evaluating Kevzara in severely or critically ill patients hospitalized with COVID-19 fails to meet primary endpoint and key secondary endpoint.
Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology have a collaboration to develop antibody therapies for treating COVID-19.
Gilead's Veklury Gets FDA Nod for Expanded Use in Coronavirus
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used to treat all hospitalized patients with COVID-19, in addition to severe COVID-19.
Gilead (GILD) Down 9.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $65.26 in the latest trading session, marking a -0.44% move from the prior day.
Biotech Industry Near-Term Outlook Modest Amid Coronavirus
by Zacks Equity Research
With the coronavirus outbreak refusing to subside anytime soon, biotech companies gain focus as they race against time to evaluate every possible therapy to break the chain.
FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus
by Kinjel Shah
Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.
Regeneron Gains on Coronavirus Treatment Development Efforts
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.
Company News for Aug 20, 2020
by Zacks Equity Research
Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.
Regeneron, Roche to Distribute Antibody Cocktail for Coronavirus
by Zacks Equity Research
Regeneron (REGN) teams up with Roche to develop and distribute REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19.
Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug
by Zacks Equity Research
Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.
Gilead Expands Collaboration With Tango for Cancer Therapies
by Zacks Equity Research
Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.
Roche Gets FDA Nod for Nervous System Disorder Drug Enspryng
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for NMOSD drug under the brand name, Enspryng.
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
How Will Biotech ETFs React to Q2 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
The Zacks Analyst Blog Highlights: Google, NVIDIA, Costco, Gilead Sciences and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, NVIDIA, Costco, Gilead Sciences and Morgan Stanley
Top Research Reports for Alphabet, NVIDIA & Costco
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), NVIDIA (NVDA) and Costco Wholesale (COST).
Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.
Gilead Sciences (GILD) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -23.97% and -1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.